Clinical Trial

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-08-26; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2025-10-27
Trial Details
NCT Number NCT05521438
Lead Sponsor Quoin Pharmaceuticals
Conditions Netherton Syndrome
Enrollment 30 participants
Start Date 2022-06-23
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-16